Estrogen therapy and coronary-artery calcification.
By J. Manson, Matthew A. Allison, J. Rossouw, J. Carr, Robert D. Langer, J. Hsia, Lewis H. Kuller, Barbara B. Cochrane, J. Hunt, S. Ludlam and 8 more. New England Journal of Medicine, 2007
687 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Radiology, Nuclear Medicine and Imaging, Surgery
View Paper: https://www.semanticscholar.org/paper/fbaef9aea725f0bce48615b302015eb50ca785e5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
Citations in the corpus
- The 2012 Hormone Therapy Position Statement of The North American Menopause Society (2012, positive): “In an ancillary substudy of younger women (G60 y) in the WHI ET trial, after an average of 7 years of treatment, women who had been randomized to ET had lower levels of coronary artery calcium than did those randomized to placebo.(44) Although the effect in older women was not evaluated, these findi”
- Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014, background): “Subsequent analyses of these data showed no increase in cardiovascular disease in women starting treatment within 10 years of menopause [82].”
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers with Cancer Risk and Mortality (2010, neutral): “The Women’s Health Initiative in postmenopausal women did not demonstrate a cardiovascular benefit overall from hormone therapy,(33) but younger women going through natural menopause may derive such benefit.(33,34) It is possible that BRCA1/2 mutation carriers undergoing abrupt surgical menopause to”
- Men: good health and high mortality. Sex differences in health and aging (2008, background): “An ancillary substudy of the WHI trial indicated that young post-menopausal women with estrogen treatment alone had lower coronary artery calcification and, thus, risk of coronary events, compared with a placebo group (71).”
- Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. (2015, background): “Composite outcomes, including revascularization (98) and coronary artery calcium scores (99), were lower with ET than with placebo.”